The House Committee on Oversight and Reform announced an investigation into the hotly debated approval and pricing of aducanumab (Aduhelm), Biogen’s new Alzheimer’s treatment. U.S. senators also called for a hearing to examine the cost to Medicare. (Fierce Pharma)
Eli Lilly said it received breakthrough therapy designation and will seek accelerated approval for its investigational anti-amyloid drug donanemab, which showed signs of slowing cognitive decline and improving function in a phase II study of early Alzheimer’s.
The FDA granted breakthrough therapy designation to another amyloid treatment candidate for Alzheimer’s, lecanemab (BAN2401), based on phase IIb study results, Eisai and Biogen announced.
Sleep is a biological necessity and is essential to health, the American Academy of Sleep Medicine said in a new position statement. (Journal of Clinical Sleep Medicine)
The American Headache Society issued an updated consensus statement on integrating new migraine treatments into clinical practice. (Headache)
Higher genetically predicted serum magnesium concentrations were associated with lower risk of intracranial aneurysm. (Neurology)
Tau PET predicted cognitive decline in preclinical and prodromal stages of Alzheimer’s disease. (JAMA Neurology)
High soluble Aβ42 peptide levels were associated with normal cognition and hippocampal volume, despite brain amyloidosis. (EClinicalMedicine)
Blarcamesine (Anavex2-73), an investigational drug that activates the sigma-1 receptor, improved cognitive and motor symptoms in a phase II trial of people with Parkinson’s disease dementia, Anavex Life Sciences announced.
The first of a series of articles in The Guardian looks at how COVID may trigger chronic pain.
Brain tissue analysis of eight people who died with severe COVID-19 showed extensive signs of inflammation and neurodegeneration, but no molecular traces of SARS-CoV-2. (Nature)
Could SARS-CoV-2 cause tauopathy? (Lancet Neurology)
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
